Insmed, Tercica Head To Court Over Growth Hormone Patents
This article was originally published in The Pink Sheet Daily
Executive Summary
A San Francisco federal court denied four of Insmed’s five motions for summary judgment, sending the dispute over iPlex and Increlex to trial in November.